As treatment options for Parkinson disease (PD) continue to expand, clinicians increasingly have to consider when patients ...
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of ...
Unlike the antiseizure medications used to manage Dravet syndrome, which act on downstream targets to modulate seizure ...
Mitzi Joi Williams, MD, is joined by Jakai McEwen, DO, and Charnetta Colton-Poole, MD, to discuss the challenges of ...
Lundbeck recently announced that its Lu AF28996, an investigational oral prodrug of a D1-like/D2-like dopamine receptor agonist, was associated with increases in good ON-time and ...
The associate vice president of clinical research at the Parkinson's Foundation discussed a large-scale replication of rs3115534-G, a noncoding GBA1 variant tied to Parkinson disease in people of ...
Extracellular vesicle scores largely remained stable on placebo, whereas KP405 was associated with statistically significant but variable within-subject shifts in insulin signaling, neuroprotection, ...
On September 17, 2026, NeurologyLive convened a clinical forum in Philadelphia titled "Recognizing and Treating Plexiform ...
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson ...
Cerebral palsy (CP) is the most common motor disability of childhood, a group of permanent movement disorders caused by a ...
Phase 3 randomized-withdrawal data in pediatrics indicated relapse in 41.9% continuing ecopipam versus 68.1% on placebo, a 53% relative relapse-risk reduction (HR, 0.50; P = .008). New analyses from ...
A 28-day, single-center, double-blind phase 1 study randomized PD participants (Hoehn and Yahr ≤3; minimal fluctuations/dyskinesia) to ARV-102 20/40/80 mg QD or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results